Weekly Recap: FDA OK for EB613 Phase 3 and $275M raise into 2030
Entera Bio Ltd. (NASDAQ:ENTX) secured FDA positive feedback on its EB613 Phase 3—~750 postmenopausal women with 12—month hip BMD primary endpoint and topline data due H2 2028—after an oversubscribed July 2026 $275M private placement that funds the program into 2030.Previous Week RecapThis is an AI…